|
Delayed
OTC Markets
09:33:35 2025-06-24 EDT
|
5-day change | 1st Jan Change | ||
| 0.2200 USD | -56.00% |
|
-.--% | - |
| 08-31 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-30 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
Company Valuation: Recce Pharmaceuticals Ltd
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 158.1 | 111.4 | 122.4 | 83.63 | 117.1 | 108.5 | - |
| Change | - | -29.54% | 9.86% | -31.67% | 40.05% | -7.32% | - |
| Enterprise Value (EV) 1 | 158.1 | 113 | 126.8 | 73.18 | 117.1 | 133.5 | 60.45 |
| Change | - | -28.55% | 12.25% | -42.29% | 60.04% | 14% | -54.72% |
| P/E | -14.1x | -8.31x | -6.02x | -3.21x | -7.83x | -4.35x | 3.33x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.4x | -0.2x | 0.34x | 0.2x | -0.1x | -0x |
| Capitalization / Revenue | - | 25.8x | 23.4x | 10.9x | 11.8x | 8.69x | 2x |
| EV / Revenue | - | 26.2x | 24.2x | 9.5x | 11.8x | 10.7x | 1.11x |
| EV / EBITDA | - | -8.83x | -7.69x | -3.69x | -9.01x | -6.08x | 1.68x |
| EV / EBIT | - | -8.9x | -7.53x | -3.63x | -8.8x | -5.97x | 1.68x |
| EV / FCF | - | -8.88x | -9.64x | -3.58x | - | -5.39x | 1.81x |
| FCF Yield | - | -11.3% | -10.4% | -28% | - | -18.6% | 55.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.0631 | -0.0752 | -0.0997 | -0.0904 | -0.0517 | -0.085 | 0.111 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 4.311 | 5.236 | 7.705 | 9.939 | 12.5 | 54.3 |
| EBITDA 1 | - | -12.8 | -16.49 | -19.81 | -13 | -21.96 | 36 |
| EBIT 1 | - | -12.69 | -16.83 | -20.17 | -13.3 | -22.35 | 35.9 |
| Net income 1 | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 | -25.1 | 33.4 |
| Net Debt 1 | - | 1.562 | 4.415 | -10.45 | - | 24.96 | -48.1 |
| Reference price 2 | 0.8900 | 0.6250 | 0.6000 | 0.2900 | 0.4050 | 0.3700 | 0.3700 |
| Nbr of stocks (in thousands) | 177,647 | 178,254 | 203,987 | 288,372 | 289,183 | 305,770 | - |
| Announcement Date | 8/31/22 | 8/31/23 | 8/30/24 | 8/29/25 | 8/31/26 | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.96x | 11.62x | 23.56x | 0.62% | 1,001B | |
| 29.63x | - | - | 2.02% | 642B | |
| 32.65x | 7.56x | 15.72x | 2.69% | 451B | |
| 18.78x | 4.58x | 11.35x | 2.9% | 340B | |
| 19.52x | 5.11x | 12.66x | 3.19% | 263B | |
| 20.44x | 4.2x | 12.01x | 2.1% | 247B | |
| 24.19x | 6.38x | 11.35x | 2.64% | 207B | |
| 12.74x | 4.63x | 9.67x | 3.94% | 197B | |
| -43.8x | 6.4x | 24.98x | 2.27% | 180B | |
| Average | 16.23x | 6.31x | 15.16x | 2.48% | 391.82B | |
| Weighted average by Cap. | 23.23x | 7.75x | 17.18x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RCE Stock
- RECEF Stock
- Valuation Recce Pharmaceuticals Ltd
Select your edition
All financial news and data tailored to specific country editions
